Tzivelekis S, Orange J, Poulos C, Meckley LM, Peay H, Sutphin J, Hernandez-Trujillo VP, Wasserman RL. Development of a novel shared decision making aid for primary immunodeficiency diseases. Immunotherapy. 2023 Jun;15(9):647-56. doi: 10.2217/imt-2022-0193
Anderson-Smits C, Park M, Bell J, Mitchell S, Hartley L, Hawe E. Subcutaneous immunoglobulin use in immunoglobulin-naïve patients with primary immunodeficiency: a systematic review. Immunotherapy. 2022 Apr;14(5):373-87. doi: 10.2217/imt-2021-0265
Jimenez-Murcia S, Fernandez-Aranda F, Granero R, Choliz M, La Verde M, Aguglia E, Signorelli MS, Sa GM, Aymami N, Gomez-Pena M, del Pino-Gutierrez A, Moragas L, Fagundo AB, Sauchelli S, Fernandez-Formoso JA, Menchon JM. Video game addiction in gambling disorder: clinical, psychopathological, and personality correlates. Biomed Res Int. 2014;2014:315062. doi: 10.1155/2014/315062
Walker EA, Picker MJ, Granger AL, Dykstra LA. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther. 2004 Jul;310(1):150-8.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Allen RM, Granger AL, Dykstra LA. Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys. J Pharmacol Exp Ther. 2002 Feb 1;300(2):435-41.